Navigation Links
Valeritas Announces Appointment of New CFO
Date:3/17/2010

BRIDGEWATER, N.J., March 17 /PRNewswire/ -- Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that it has hired James E. Dentzer to serve as its Chief Financial Officer.

Dentzer brings a wealth of experience to Valeritas, with his most recent success as Chief Financial Officer of Amicus Therapeutics where he led the company in closing a Series D private financing and executing a successful IPO.

"We are extremely pleased to welcome Jim to the Valeritas executive team," said Kristine Peterson, Chief Executive Officer, Valeritas.  "He brings the financial experience Valeritas needs as we continue to advance the development of our products. This is an exciting stage in our company's growth and Jim's strong track record for taking companies public, helping organizations finance their growth, and his proven commercialization experience makes him ideal for our organization."  

"Joining Valeritas at this important time is very exciting," said Dentzer.  "With the company's strong set of current investors committed to the company's organizational needs, Valeritas is positioned to be a major player in the diabetes space.  I am proud to have joined an organization that can provide life-changing therapeutic options to people suffering with this condition."

Dentzer joined Amicus Therapeutics as Chief Financial Officer in October 2006 where he supported the organization through its IPO.  Prior to joining Amicus, he was Vice President and Corporate Controller of Biogen Idec and held various senior financial roles at E.I. du Pont de Nemours and Company.

About Valeritas, Inc.

Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes.  Valeritas' medical technologies portfolio is headlined by the h-Patch™ technology.  The first use of the h-Patch™ technology will be the V-Go™ Disposable Insulin Delivery Device for the simple delivery of basal-bolus therapy via a preset basal rate and on-demand bolus dosing around mealtimes.

In addition to the V-Go™, Valeritas' delivery technology portfolio includes the h-Patch™ for the delivery of other compounds beyond insulin, the Mini-Ject™ Pre-Filled Needle-Free Delivery System, and the Micro-Trans™ Microneedle Transdermal Delivery Patch.  These technologies, when combined with certain compounds, are designed to provide unique products that allow precise dosing in previously difficult to treat conditions.

Headquartered in Bridgewater, N.J., Valeritas operates its R&D and manufacturing in a state-of-the-art facility in Shrewsbury, Massachusetts. Valeritas primary investors include: MPM Capital, Pitango Venture Capital, Abingworth, US Venture Partners, Onset Ventures, Advanced Technology Ventures, HLM Venture Partners, CHL Medical Partners, and Kaiser Permanente Ventures.

SOURCE Valeritas, Inc.

Back to top
'/>"/>
SOURCE Valeritas, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Valeritas Hires Trade and Distribution Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
2. Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
3. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
4. Valeritas Announces Appointment of New CEO
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... active R&D program for the development of future natural products ... unique research and development center in Israel ... Stockton has a variety of products ... is active in more than 35 counties worldwide. ... flagship product Timorex Gold ® is used to ...
(Date:2/5/2016)... ATCC, the premier global biological materials resource ... and life science researchers that are working to address ... CDC website . --> CDC ... a single-stranded RNA virus of the Flaviviridae family, genus ... Chikungunya Viruses. Zika virus is transmitted to humans primarily ...
(Date:2/4/2016)... , ... February 04, 2016 , ... ... development and compliance training, today announced an interactive FDA compliance training ... The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently ...
(Date:2/4/2016)... Beike Biotechnology, the Shenzhen ... ceremony in late 2015 to mark their successful combined ... --> --> The ... Cell Therapy" was hosted by the Shenzhen Cell Bank ... of Beike Biotechnology Co., Ltd. Shenzhen,s ...
Breaking Biology Technology:
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
(Date:1/21/2016)... January 21, 2016 ... new market research report "Emotion Detection and Recognition Market by ... Tools (Facial Expression, Voice Recognition and Others), Services, ... forecast to 2020", published by MarketsandMarkets, the global ... reach USD 22.65 Billion by 2020, at a ...
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):